형광 제자리 부합법 프로브 시장 규모, 점유율, 동향 분석 보고서 : 기술별, 유형별, 용도별, 최종 용도별, 부문별 예측(2023년-2030년)

Fluorescent In Situ Hybridization Probe Market Size, Share & Trends Analysis Report By Technology, By Type, By Application, By End-use, And Segment Forecasts, 2023 - 2030

US $ 4,950 ￦ 7,024,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 5,950 ￦ 8,443,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 7,950 ￦ 11,281,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

형광 제자리 부합법(FISH) 프로브 시장의 성장과 동향 :

FISH 프로브 세계 시장 규모는 예측 기간 동안 복합 연간 성장률(CAGR) 7.6%로 성장하여 2030년까지 14억 9,000만 달러에 달할 것으로 예측됩니다.

암과 같은 대상질환에 걸리기 쉬운 세계 인구 증가가 정확하고 효과적인 진단에 대한 수요 증가로 이어지고 있습니다. 이것이 시장 성장을 밀어 올릴 것으로 예상됩니다. 예를 들어 American Cancer Society Cancer Statistics 2023에 따르면 미국에서는 2023년에 약 190만명이 새롭게 암으로 진단될 것으로 추정되고 있습니다. 호주 보건복지연구소(AIHW)의 2021년 보고서에 따르면 호주는 2021년에 150,782명의 신규암 환자가 발생할 것으로 추정되고 있습니다.

게다가 ICMR의 2021년 보고서에 따르면 인도의 암 환자수는 2021년 2,670만명에서 2025년에는 2,980만명으로 증가할 것으로 예측되고 있습니다. FISH(FISH) 기술은 특정 DNA 서열의 정확한 국소화, 유전병 진단, 유전자 매핑, 다양한 유형의 암과 관련된 새로운 암 유전자의 동정 등 다양한 목적 도움이 됩니다. 암 유전체에 대한 투자 증가는 FISH 채택과 중요성을 촉진할 것으로 예상됩니다. 게다가 정부의 지원 방안, 건강 관리 지출 수준의 상승, 이 기술과 관련된 이점에 대한 의식 증가는 예측 기간 동안 업계의 성장을 가속할 것으로 예상됩니다.

또한, 장기간의 연구를 위한 분석 샘플의 보존 시간의 연장과 같은 발색 in situ 하이브리드화(CISH)의 기술적 진보는 향후 수년간 내비게이션 시스템 수요를 촉진할 것으로 예상됩니다. FISH는 안젤만 증후군, 프라다 윌리 증후군, 만성 골수성 백혈병, 다운 증후군, 심장혈관 안면 증후군, 22q13 결실 증후군, 급성 림프 아구성 백혈병(ALL), 클리 듀 채팅 등의 유전성 질병의 검출에 가장 일반적으로 사용됩니다. 2022년 CDC 발표에 따르면, 다운증후군은 가장 흔한 유전병이며 신생아의 약 700명 중 1명이 앓고 있습니다.

이 질병의 유병률이 증가함에 따라 이러한 유전성 질환을 검출하기 위한 효율적인 진단법을 제공할 필요성이 높아지고 있으며, 나아가 시장 전체의 성장을 견인하고 있습니다. 또한 주요 진입기업은 세계 발자국을 확대하고 시장에서 경쟁력을 유지하기 위해 제품 출시, 제휴, 협력, M&A 등 다양한 전략을 추진하고 있습니다. 예를 들어, 2023년 3월, OGT(시스멕스 그룹)는 CytoCell FISH 프로브의 IVDR 인증을 획득했습니다. 이 회사는 IVDR 인증을 받은 최초의 FISH 프로브 제조업체로 현저히 엄격한 규제 기준을 충족하기 위한 흔들림 없는 헌신을 보여줍니다. 이 인증은 회사 제품의 지속적인 안전성, 신뢰성 및 유효성을 입증합니다.

형광 제자리 부합법(FISH) 프로브 시장 보고서 하이라이트

• 기술별로는 세균성, 바이러스성, 진균성 질환의 진단에 높은 수요가 있기 때문에 플로 FISH 분야가 2022년 시장을 독점했습니다.
• 유형별로는 miRNA는 연구개발 증가나 암 검출에 있어서의 miRNA의 광범위한 사용 등의 요인에 의해 예측기간 중에 높은 복합 연간 성장률(CAGR)로 성장할 것으로 예측됩니다.
• 용도별로는 인구 사이에서 암 유병률이 상승하고 있기 때문에 암 진단이 2022년 시장을 독점하고 있습니다.
• 아시아태평양은 대상 질환의 유병률 증가, 건강 관리 시설 개선, 질병 검출을 위한 체외 진단용 의약품 수요 증가로 예측 기간 동안 가장 빠른 복합 연간 성장률(CAGR)로 성장할 것으로 예상됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 FISH 프로브 시장 변수, 동향 및 범위

• 시장 세분화 및 범위
• 시장 계통 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
• 시장 성장 억제요인 분석
• Porter's Five Forces 분석
• PESTLE 분석
• 파이프라인 분석

제4장 FISH 프로브 시장 : 기술 추정 및 동향 분석

• FISH 프로브 시장 : 기술 변동 분석
• Q FISH
• 플로 FISH
• 기타 FISH

제5장 FISH 프로브 시장 : 유형의 추정 및 동향 분석

• FISH 프로브 시장 : 유형의 변동 분석
• DNA
• RNA

제6장 FISH 프로브 시장 : 용도의 추정 및 동향 분석

• FISH 프로브 시장 : 용도의 변동 분석
• 암 조사
• 유전병
• 기타

제7장 FISH 프로브 시장 : 최종 용도 추정 및 동향 분석

• FISH 프로브 시장 : 최종 용도의 변동 분석
• 조사
• 임상
• 컴패니언 진단

제8장 FISH 프로브 시장 : 지역 비즈니스 분석

• 지역 시장 현황
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제9장 경쟁 구도

• 기업의 분류
• 전략 매핑
  • 신제품 발매
  • 파트너십
  • 취득
  • 콜라보레이션
  • 자금 제공
• 주요 기업의 시장 점유율 분석(2022년)
• 기업 히트맵 분석
• 기업 프로파일
  • THERMO FISHER SCIENTIFIC INC.
  • PERKINELMER INC
  • BIODOT
  • HORIZON DIAGNOSTICS
  • MERCK KGAA
  • AGILENT TECHNOLOGIES
  • ABNOVA CORPORATION
  • LGC BIOSEARCH TECHNOLOGIES INC.
  • GENEMED BIOTECHNOLOGIES, INC.
  • F. HOFFMANN-LA ROCHE LTD
  • OXFORD GENE TECHNOLOGY
  • BIOCARE MEDICAL, LLC
  • QIAGEN(EXIQON A/S)
  • GSP RESEARCH INSTITUTE, INC.

BJH

영문 목차

영문목차

Fluorescent In Situ Hybridization Probe Market Growth & Trends:

The global fluorescent in situ hybridization probe market size is expected to reach USD 1.49 billion by 2030, registering a CAGR of 7.6% over the forecast period. The increasing global population being prone to target diseases, such as cancer, leads to the rising demand for accurate and effective diagnostics. This is expected to boost the market growth. For instance, according to the American Cancer Society Cancer Statistics 2023, it was estimated that approximately 1.9 million new cancer cases will be diagnosed in the U.S. in 2023. The Australian Institute of Health and Welfare (AIHW) 2021 report indicates that there were an estimated 150,782 new cancer cases in Australia in 2021.

Furthermore, the ICMR 2021 Report suggests that the number of cancer patients in India is projected to increase from 26.7 million in 2021 to 29.8 million in 2025. The fluorescent in situ hybridization (FISH) technique serves various purposes, including the precise localization of specific DNA sequences, genetic disease diagnosis, gene mapping, and identification of new oncogenes associated with different types of cancers. The growing investment in cancer genomics is expected to drive the adoption and significance of FISH. In addition, supportive government initiatives, rising healthcare expenditure levels, and increasing awareness pertaining to the benefits associated with this technique are expected to fuel industry growth during the forecast period.

Furthermore, technological advancement in chromogenic in situ hybridization (CISH), such as higher storage time of analyzed samples for long-duration studies, is expected to fuel the demand for navigation systems in the coming years. FISH is most commonly used in the detection of genetic diseases, such as Angelman syndrome, Prader-Willi syndrome, chronic myelogenous leukemia, Down's syndrome, Velocardiofacial syndrome, 22q13 deletion syndrome, acute lymphoblastic leukemia (ALL), and cri-du-chat. According to a publication from the CDC in 2022, Down's syndrome is the most common genetic disorder, with almost one in every 700 newborns affected by the disorder.

The rising prevalence of the condition drives the need to provide efficient diagnostics for detecting these genetic diseases, which, in turn, drives the overall market growth. Furthermore, key participants are engaged in various strategies, such as product launches, partnerships & collaborations, and M&As, to expand their global footprint and maintain competitive position in the market. For instance, in March 2023, OGT (Sysmex Group) received IVDR certification for CytoCell FISH probes. The company is the first manufacturer of FISH probes to receive IVDR certification, showcasing its unwavering commitment to meeting the significantly more rigorous regulatory standards. This certification validates their products' enduring safety, dependability, and efficacy.

Fluorescent in Situ Hybridization Probe Market Report Highlights:

• On the basis of technology, the flow FISH segment dominated the market in 2022 owing to the high demand for diagnosis of bacterial, viral, and fungal diseases
• On the basis of type, miRNA is anticipated to grow at a significant CAGR over the forecast period driven by factors, such as increasing R&D and extensive usage of miRNA in cancer detection
• Based on applications, cancer diagnostics dominated the market with market in 2022 due to the rising prevalence of cancer among the population
• Asia Pacific is expected to register the fastest CAGR over the forecast period due to the rising prevalence of target diseases, improving healthcare facilities, and growing demand for IVD testing for disease detection

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Technology Segment
    • 1.1.1.2. Type Segment
    • 1.1.1.3. Application Segment
    • 1.1.1.4. End-use segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Technology and Type Snapshot
• 2.3. Application and End Use Snapshot
• 2.4. Competitive Landscape Snapshot

Chapter 3. FISH Probe Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Restraint Analysis
• 3.5. Porter's Five Forces Analysis
• 3.6. PESTLE Analysis
• 3.7. Pipeline Analysis

Chapter 4. FISH Probe Market: Technology Estimates & Trend Analysis

• 4.1. Fish Probe Market: Technology Movement Analysis
• 4.2. Q FISH
  • 4.2.1. Q FISH market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.3. FLOW FISH
  • 4.3.1. FLOW FISH market estimates and forecasts, 2018 - 2030 (USD Million)
• 4.4. Other FISH
  • 4.4.1. Other FISH market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. FISH Probe Market: Type Estimates & Trend Analysis

• 5.1. FISH Probe Market: Type Movement Analysis
• 5.2. DNA
  • 5.2.1. DNA market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.3. RNA
  • 5.3.1. RNA market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.3.2. mRNA
    • 5.3.2.1. mRNA market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.3.3. miRNA
    • 5.3.3.1. miRNA market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.3.4. Others
    • 5.3.4.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. FISH Probe Market: Application Estimates & Trend Analysis

• 6.1. FISH Probe Market: Application Movement Analysis
• 6.2. Cancer Research
  • 6.2.1. Cancer Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.2.2. Lung
    • 6.2.2.1. Lung market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.2.3. Breast
    • 6.2.3.1. Breast market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.2.4. Bladder
    • 6.2.4.1. Bladder market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.2.5. Hematological
    • 6.2.5.1. Hematological market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.2.6. Gastric
    • 6.2.6.1. Gastric market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.2.7. Prostrate
    • 6.2.7.1. Prostrate market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.2.8. Cervical
    • 6.2.8.1. Cervical market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.2.9. Others
    • 6.2.9.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.3. Genetic Diseases
  • 6.3.1. Genetic Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Other
  • 6.4.1. Other Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. FISH Probe Market: End-use Estimates & Trend Analysis

• 7.1. Fish Probe Market: End-use Movement Analysis
• 7.2. Research
  • 7.2.1. Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.3. Clinical
  • 7.3.1. Clinical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Companion Diagnostics
  • 7.4.1. Companion Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. FISH Probe Market: Regional Business Analysis

• 8.1. Regional Market Snapshot
• 8.2. North America
  • 8.2.1. North America FISH Probe Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. U.S. FISH Probe Market, 2018 - 2030 (USD Million)
    • 8.2.2.2. Key Country Dynamics
    • 8.2.2.3. Regulatory Framework
    • 8.2.2.4. Reimbursement Scenario
    • 8.2.2.5. Competitive Scenario
  • 8.2.3. CANADA
    • 8.2.3.1. Canada FISH Probe Market, 2018 - 2030 (USD Million)
    • 8.2.3.2. Key Country Dynamics
    • 8.2.3.3. Regulatory Framework
    • 8.2.3.4. Reimbursement Scenario
    • 8.2.3.5. Competitive Scenario
• 8.3. Europe
  • 8.3.1. Europe FISH Probe Market, 2018 - 2030 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. UK FISH Probe Market, 2018 - 2030 (USD Million)
    • 8.3.2.2. Key Country Dynamics
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. Reimbursement Scenario
    • 8.3.2.5. Competitive Scenario
  • 8.3.3. GERMANY
    • 8.3.3.1. Germany FISH Probe Market, 2018 - 2030 (USD Million)
    • 8.3.3.2. Key Country Dynamics
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Reimbursement Scenario
    • 8.3.3.5. Competitive Scenario
  • 8.3.4. SPAIN
    • 8.3.4.1. Spain FISH Probe Market, 2018 - 2030 (USD Million)
    • 8.3.4.2. Key Country Dynamics
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Reimbursement Scenario
    • 8.3.4.5. Competitive Scenario
  • 8.3.5. FRANCE
    • 8.3.5.1. France FISH Probe Market, 2018 - 2030 (USD Million)
    • 8.3.5.2. Key Country Dynamics
    • 8.3.5.3. Regulatory Framework
    • 8.3.5.4. Reimbursement Scenario
    • 8.3.5.5. Competitive Scenario
  • 8.3.6. ITALY
    • 8.3.6.1. Italy FISH Probe Market, 2018 - 2030 (USD Million)
    • 8.3.6.2. Key Country Dynamics
    • 8.3.6.3. Regulatory Framework
    • 8.3.6.4. Reimbursement Scenario
    • 8.3.6.5. Competitive Scenario
  • 8.3.7. DENMARK
    • 8.3.7.1. Denmark FISH Probe Market, 2018 - 2030 (USD Million)
    • 8.3.7.2. Key Country Dynamics
    • 8.3.7.3. Regulatory Framework
    • 8.3.7.4. Reimbursement Scenario
    • 8.3.7.5. Competitive Scenario
  • 8.3.8. SWEDEN
    • 8.3.8.1. Sweden FISH Probe Market, 2018 - 2030 (USD Million)
    • 8.3.8.2. Key Country Dynamics
    • 8.3.8.3. Regulatory Framework
    • 8.3.8.4. Reimbursement Scenario
    • 8.3.8.5. Competitive Scenario
  • 8.3.9. NORWAY
    • 8.3.9.1. Norway FISH Probe Market, 2018 - 2030 (USD Million)
    • 8.3.9.2. Key Country Dynamics
    • 8.3.9.3. Regulatory Framework
    • 8.3.9.4. Reimbursement Scenario
    • 8.3.9.5. Competitive Scenario
• 8.4. Asia Pacific
  • 8.4.1. Asia-Pacific FISH Probe Market, 2018 - 2030 (USD Million)
  • 8.4.2. JAPAN
    • 8.4.2.1. Japan FISH Probe Market, 2018 - 2030 (USD Million)
    • 8.4.2.2. Key Country Dynamics
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Scenario
    • 8.4.2.5. Competitive Scenario
  • 8.4.3. CHINA
    • 8.4.3.1. China FISH Probe Market, 2018 - 2030 (USD Million)
    • 8.4.3.2. Key Country Dynamics
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Scenario
    • 8.4.3.5. Competitive Scenario
  • 8.4.4. INDIA
    • 8.4.4.1. India FISH Probe Market, 2018 - 2030 (USD Million)
    • 8.4.4.2. Key Country Dynamics
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Scenario
    • 8.4.4.5. Competitive Scenario
  • 8.4.5. SOUTH KOREA
    • 8.4.5.1. South Korea FISH Probe Market, 2018 - 2030 (USD Million)
    • 8.4.5.2. Key Country Dynamics
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Reimbursement Scenario
    • 8.4.5.5. Competitive Scenario
  • 8.4.6. THAILAND
    • 8.4.6.1. Thailand FISH Probe Market, 2018 - 2030 (USD Million)
    • 8.4.6.2. Key Country Dynamics
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Reimbursement Scenario
    • 8.4.6.5. Competitive Scenario
  • 8.4.7. AUSTRALIA
    • 8.4.7.1. Australia FISH Probe Market, 2018 - 2030 (USD Million)
    • 8.4.7.2. Key Country Dynamics
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Reimbursement Scenario
    • 8.4.7.5. Competitive Scenario
• 8.5. Latin America
  • 8.5.1. Latin America FISH Probe Market, 2018 - 2030 (USD Million)
  • 8.5.2. BRAZIL
    • 8.5.2.1. Brazil FISH Probe Market, 2018 - 2030 (USD Million)
    • 8.5.2.2. Key Country Dynamics
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Scenario
    • 8.5.2.5. Competitive Scenario
  • 8.5.3. MEXICO
    • 8.5.3.1. Mexico FISH Probe Market, 2018 - 2030 (USD Million)
    • 8.5.3.2. Key Country Dynamics
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Scenario
    • 8.5.3.5. Competitive Scenario
  • 8.5.4. ARGENTINA
    • 8.5.4.1. Argentina FISH Probe Market, 2018 - 2030 (USD Million)
    • 8.5.4.2. Key Country Dynamics
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Reimbursement Scenario
    • 8.5.4.5. Competitive Scenario
• 8.6. MEA
  • 8.6.1. MEA FISH Probe Market, 2018 - 2030 (USD Million)
  • 8.6.2. SOUTH AFRICA
    • 8.6.2.1. South Africa FISH Probe Market, 2018 - 2030 (USD Million)
    • 8.6.2.2. Key Country Dynamics
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Scenario
    • 8.6.2.5. Competitive Scenario
  • 8.6.3. SAUDI ARABIA
    • 8.6.3.1. Saudi Arabia FISH Probe Market, 2018 - 2030 (USD Million)
    • 8.6.3.2. Key Country Dynamics
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Scenario
    • 8.6.3.5. Competitive Scenario
  • 8.6.4. UAE
    • 8.6.4.1. UAE FISH Probe Market, 2018 - 2030 (USD Million)
    • 8.6.4.2. Key Country Dynamics
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Scenario
    • 8.6.4.5. Competitive Scenario
  • 8.6.5. KUWAIT
    • 8.6.5.1. Kuwait FISH Probe Market, 2018 - 2030 (USD Million)
    • 8.6.5.2. Key Country Dynamics
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Scenario
    • 8.6.5.5. Competitive Scenario

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
  • 9.2.1. NEW PRODUCT LAUNCH
  • 9.2.2. PARTNERSHIPS
  • 9.2.3. ACQUISITION
  • 9.2.4. COLLABORATION
  • 9.2.5. FUNDING
• 9.3. Key Company Market Share Analysis, 2022
• 9.4. Company Heat Map Analysis
• 9.5. Company Profiles
  • 9.5.1. THERMO FISHER SCIENTIFIC INC.
    • 9.5.1.1. Company Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. PERKINELMER INC
    • 9.5.2.1. Company Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. BIODOT
    • 9.5.3.1. Company Overview
    • 9.5.3.2. Product Benchmarking
    • 9.5.3.3. Strategic Initiatives
  • 9.5.4. HORIZON DIAGNOSTICS
    • 9.5.4.1. Company Overview
    • 9.5.4.2. Product Benchmarking
    • 9.5.4.3. Strategic Initiatives
  • 9.5.5. MERCK KGAA
    • 9.5.5.1. Company Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. AGILENT TECHNOLOGIES
    • 9.5.6.1. Company Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. ABNOVA CORPORATION
    • 9.5.7.1. Company Overview
    • 9.5.7.2. Product Benchmarking
    • 9.5.7.3. Strategic Initiatives
  • 9.5.8. LGC BIOSEARCH TECHNOLOGIES INC.
    • 9.5.8.1. Company Overview
    • 9.5.8.2. Product Benchmarking
    • 9.5.8.3. Strategic Initiatives
  • 9.5.9. GENEMED BIOTECHNOLOGIES, INC.
    • 9.5.9.1. Company Overview
    • 9.5.9.2. Product Benchmarking
    • 9.5.9.3. Strategic Initiatives
  • 9.5.10. F. HOFFMANN-LA ROCHE LTD
    • 9.5.10.1. Company Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic Initiatives
  • 9.5.11. OXFORD GENE TECHNOLOGY
    • 9.5.11.1. Company Overview
    • 9.5.11.2. Product Benchmarking
    • 9.5.11.3. Strategic Initiatives
  • 9.5.12. BIOCARE MEDICAL, LLC
    • 9.5.12.1. Company Overview
    • 9.5.12.2. Product Benchmarking
    • 9.5.12.3. Strategic Initiatives
  • 9.5.13. QIAGEN (EXIQON A/S)
    • 9.5.13.1. Company Overview
    • 9.5.13.2. Financial Performance
    • 9.5.13.3. Product Benchmarking
    • 9.5.13.4. Strategic Initiatives
  • 9.5.14. GSP RESEARCH INSTITUTE, INC.
    • 9.5.14.1. Company Overview
    • 9.5.14.2. Product Benchmarking
    • 9.5.14.3. Strategic Initiatives

관련자료